Drug prices in the United States significantly exceed those in Switzerland and Europe, a claim supported by Trump.
=========================================================================
In the pharmaceutical sector, the Trump administration has identified two key issues: high medicine prices in the USA and the industry's contribution to the large trade deficit of the USA with Switzerland.
Switzerland, a high-priced country for medicines, has become a major supplier of patented and critical drugs to the USA. In 2024, the country had a trade surplus of around 39 billion francs with the USA, and nearly half of Switzerland's goods exports to the USA were pharmaceutical products.
Swiss pharmaceutical exports to the US total around $38-48 billion annually, making them a significant contributor to Switzerland's trade surplus. The high-value, patented medicines produced by major Swiss pharmaceutical firms like Novartis and Roche, including critical cancer treatments, sustain strong demand in the US market despite its high prices.
The Swiss pharma industry's reputation for high-quality production and innovation allows it to command strong export volumes. US tariffs and trade tensions partly aim to pressure Switzerland to lower drug prices, reflecting the US concern over high medicine costs rather than low Swiss export volume.
While pharma is a major contributor, other factors also influence Switzerland’s trade surplus with the US, such as gold exports. Without gold, the surplus would reduce but still be substantial from pharma exports alone.
US tariffs target Switzerland's trade surplus but exclude pharmaceuticals temporarily due to their critical role in US healthcare. This exemption underlines the sector's importance despite tensions over pricing.
In summary, Switzerland's pharmaceutical sector exports high-value, patented medicines that remain in strong demand in the US market despite its high prices, making pharma a major driver of Switzerland's trade surplus with the USA. US concerns over drug prices have resulted in trade tensions and tariff discussions but have not diminished Switzerland's pharmaceutical export dominance to the US.
Note: This article requires JavaScript to function fully. Please adjust your settings to enable JavaScript on NZZ.ch.
- The Trump administration's focus on economic and social policy includes the issue of high medicine prices in the USA, and it is particularly concerned about the significant contribution of the Swiss pharmaceutical industry, with companies like Novartis and Roche, to this problem due to their high-priced, patented medicines, especially critical cancer treatments, that sustain strong demand in the US market.
- In the arena of health-and-wellness, finance, and economic and social policy, Switzerland's pharmaceutical sector has become a vital pillar in the country's industry, garnering a substantial trade surplus with the USA through exports worth around $38-48 billion annually. These exports, comprising high-value, patented medicines, are also crucial to US healthcare, hence temporary exemptions from US tariffs. However, despite tensions over pricing, the Swiss pharma industry maintains its dominance in the US market.
